Differences in body mass index z-scores and weight status in a dutch pediatric psychiatric population with and without use of second-generation antipsychotics

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 2, 2012, Pages 166-173

  De Hoogd, Sjoerd ^a   Overbeek, Wieske A ^b   Heerdink, Eibert R ^b,c   Correll, Christoph U ^d   De Graeff, Elisabeth R ^b   Staal, Wouter G ^b,e,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMERICAN PSYCHIATRIC ASSOCIATION 2000; AUTISM; BODY MASS; CAUCASIAN; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 4TH EDITION TEXT REVISION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; OBESITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRESCHOOL CHILD; PRESCRIPTION; RATING SCALE; REVIEW; SCHOOL CHILD; SCORING SYSTEM; SEX DIFFERENCE; Z SCORE;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; NETHERLANDS; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84859941730     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0079     Document Type: Review

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
3. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombín I, Moreno D: Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18: 418-28, 2009.
4. Baker JL, Olsen LW, Sørensen TI: Childhood body mass index and the risk of coronary heart disease in adulthood. N. Engl. J. Med. 357:2329-2337, 2007. (Pubitemid 350223387)
5. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, Biswas SK, Ramji S, Prabhakaran D, Reddy KS: Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N. Engl. J. Med. 35:865-875, 2004. (Pubitemid 38252534)
6. Brown S, Birtwistle J, Roe L, Thompson C: The unhealthy lifestyle of people with schizophrenia. Psycholog Med 29:697-701, 1999. (Pubitemid 29261358)
7. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA: Leptin gene - 2548G/A variants predict risperidone-Associated weight gain in children and adolescents. Psychiatr Genet 19:320-327, 2009.
8. Chagnon YC, Mérette C, Bouchard RH, Emond C, Roy MA, Maziade M: A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 9:1067-1074, 2004. (Pubitemid 40065451)
9. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69(Suppl 4):26-36, 2008a.
10. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008b.
11. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 17:97-107, 2011.
12. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:242-249, 2009
13. Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116-141, 2010.
14. Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C: Efficacy and safety of secondgeneration antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621-645, 2011.
15. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 47:316-323, 2000. (Pubitemid 30127036)
16. Gentile S: Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Saf 29:303-319, 2006.
17. Gracious BL, Cook SR, Meyer AE, Chirieac MC, Malhi N, Fischetti AT, Finucane TL, Ma Y: Prevalence of overweight and obesity in adolescents with severe mental illness: A cross-sectional chart review. J Clin Psychiatry 71:949-954, 2010.
18. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144-158, 2011.
19. Hurk van den K, van Dommelen P, van Buuren S, Verkerk PH, Hirasing RA, Hirasing RA: Prevalence of overweight and obesity in the Netherlands in 2003 compared to 1980 and 1997. Arch Dis Child 92:992-995, 2007. (Pubitemid 350043973)
20. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, de Jong-van den Berg LT. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59:554-560, 2008.
21. Laita P, Cifuentes A, Doll A, Llorente C, Cortés I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C. Antipsychoticrelated abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc. Psychopharmacol. 17:487-502, 2007.
22. Luby J, Mrakotsky C, Stalets M, Belden A, Heffelfinger A, Williams M, Spitznagel E: Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc. Psychopharmacol. 16:575-587, 2006. (Pubitemid 44737212)
23. Maayan L, Correll CU: Management of antipsychotic-related weight gain. Expert Rev Neurother 10:1175-200, 2010.
24. Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C: Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 12:172-184, 2010.
25. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 164:344-51, 2010. Erratum in: Arch Pediatr Adolesc Med 164:584, 2010.
26. Nagaraj R, Singhi P, Mahli P: Risperidone in children with autism: Radomized, placebo-controlled, double-blind study. J Child Neurol 21:450-455, 2006. (Pubitemid 44069792)
27. Ogden CL, Carroll MD, Curtin RC, Lamb MM, Flegal KM: Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303:242-249, 2010.
28. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 3:679-685, 2006. (Pubitemid 43848299)
29. Rani F, Murray ML, Byrne PJ, Wong IC: Epidemiological features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002-1009, 2008.
30. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347:314-321, 2002.
31. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc. Psychopharmacol. 17:768-778, 2007. (Pubitemid 351158602)
32. Schuber I, Lehmkuhl G: Increased antipsychotic prescribing to youths in Germany. Psychiatric Serv 60:269, 2009.
33. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-e641, 2004. (Pubitemid 41647671)
34. Sinaiko AR, Donahue RP, Jacobs DR Jr., Prineas RJ: Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. Circulation 99:1471-1476, 1999. (Pubitemid 29140914)
35. Srinivasan SR, Myers L, Berenson GS: Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood. Diabetes 51:204-209, 2002. (Pubitemid 34517999)
36. Tarricone I, Gozzi BF, Serretti A, Grieco D, Berardi D: Weight gain in antipsychotic-naïve patients: A review and meta-Analysis. Psychol Med 40:187-200, 2010.
37. Winkleby MA, Robinson TN, Sundquist J, Kraemer HC: Ethnic variation in cardiovascular disease risk factors among children and young adults. JAMA 281:1006-1013, 1999.